Thomas Semrad is an Oncology physician affiliated with Tahoe Forest Hospital. OpenAlex indexes 77 publications with 1,391 citations (h-index 17); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10121 Pine Ave
Truckee, CA 961614835
Telephone
530-582-6450Provider last certified this registry record 16 May 2023.
Clinical trials
- Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Sponsor: University of California, Davis
- Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Sponsor: University of California, Davis
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20241 payment
- ABBVIE INC.Program year20241 payment
- Foundation Medicine, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.3%Aromatase Inhibitor8.5%Anastrozole71%Letrozole29%Part D<11 patientsKinase inhibitor5.6%Tagrisso51%Calquence49%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
21.4%Serotonin-3 Receptor Antagonist6.6%Ondansetron Hcl100%Part D≥21 patientsCorticosteroid6.5%Prednisone100%Part D≥13 patients+ 2 more classes in this area
Nervous system
13.3%Atypical Antipsychotic6.1%Olanzapine100%Part D≥14 patientsBenzodiazepine3.5%Lorazepam100%Part D≥15 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
Journal of Clinical Oncology
2026 - Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Journal of Clinical Oncology
2023 - A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Endocrine Related Cancer
2023 - A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
Cancer Chemotherapy and Pharmacology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”